EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells


Journal of Clinical Endocrinology and Metabolism 63(6): 1342-1347
Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells
We studied the interaction between dopamine and estradiol on PRL release by cultured normal and tumorous PRL-secreting cells prepared from human pituitaries. If pituitary glands were obtained within 3 h after sudden death of previously normal individuals, the viability of isolated pituitary cells prepared by dispersion with dispase was more than 75%. After 4 days of culture, dopamine (500 nM) inhibited PRL release by cells prepared from four normal pituitaries by 24 .+-. 3% (.+-. SEM). Pretreatment of the cells with 100 nM estradiol did not alter dopamine-mediated inhibition of PRL release. Estradiol alone increased basal PRL release and cell PRL content. Cultured PRL-secreting pituitary tumor cells, obtained by transsphenoidal operation from four patients, were simlarly sensitive to dopamine. Estradiol stimulated tumor cell PRL release and content, but significantly diminished the inhibitory effect of dopamine. The estrogen receptor blocker tamoxifen did not alter PRL release, but it did reverse the estradiol-induced insensitivity of the prolactinoma cells to the dopamine agonist bromocriptine. In conclusion, these in vitro results indicate that estrogens do not antagonize the effect of dopamine on normal human PRL-secreting pituitary cells. In human pituitary tumor cells, however, estradiol decreased the sensitivity of PRL release to dopamine (agonists), and the estrogen action can be acutely reversed by tamoxifen.


Accession: 005151336

PMID: 3782422

DOI: 10.1210/jcem-63-6-1342



Related references

Effects of 17 beta estradiol and dopamine on prolactin secretion in cultured pituitary cells. Zoological Magazine (Tokyo) 84(4): 412, 1975

Effects of 17 beta-estradiol on angiotensin II receptors and prolactin release in cultured pituitary cells. Endocrinology 119(6): 2768-2772, 1986

Characterization of dopamine and estrogen interaction on primate prolactin secretion with pituitary cells cultured on extracellular matrix and with pituitary stalk-transected monkeys. Endocrinology 116(3): 863-872, 1985

Effects of estradiol on prolactin and growth hormone messenger rna in cultured normal and neoplastic mtt w15 and gh 3 rat pituitary cells. Cancer Research 49(5): 1247-1253, 1989

Effect of clozapine on dopamine-induced inhibition of prolactin release from cultured rat pituitary cells. Pharmacological Research 35(3): 173-175, 1997

The novel dopaminergic drugs cv 205 502 and cqp 201 403 suppress prolactin and growth hormone secretion from normal rat and human tumorous pituitary cells in vitro. Journal of Endocrinology 112(SUPPL), 1987

Effects of estradiol on prolactin and growth hormone messenger RNAs in cultured normal and neoplastic (MtT/W15 and GH3) rat pituitary cells. Cancer Research 49(5): 1247-1253, 1989

Ascorbic acid potentiates the inhibitory effect of dopamine on prolactin release in primary cultured rat pituitary cells. Journal of Endocrinology 118(2): 287-294, 1988

Interactions of dopamine and neurotensin on calcium fluxes and prolactin release in normal rat pituitary cells. Endocrinology 127(4): 1948-1955, 1990

Somatostatin does not inhibit prolactin synthesis in normal male rat pituitary cells but inhibits prolactin synthesis in estradiol-primed pituitary cells. Journal of Endocrinology 148(1): 69-76, 1996